April 14-19, 2023 The BioFluidica booth at the recent American Association for Cancer Research, AACR, Annual Conference experienced much attention as scientists learned the potential of EV-subtype-based liquid biopsy exosome liquid biopsy) and the reliability of LiquidScan to enrich CTCs from whole blood to drive downstream multi-omics analysis (Poster Presentation). VIEW POSTER
February 9, 2023 Blood was drawn from 16 breast cancer patients and enriched for Circulating Tumor Cells (CTCs) using LiquidScan. Isolated cells were analyzed for HER2 positivity using FISH. Of 11 patients that tested HER2- after needle biopsy, LiquidScan revealed 2 of these to be HER2+. Except for these two patients that needle biopsy missed,...
February 9, 2023 BioFluidica attended the Precision Medicine World Conference (PMWC) 2023 on January 25-27th. Every year PMWC gathers top researchers and medical professionals from all over the world to collaborate and accelerate Precision Medicine. This 3-day showcase gave BioFluidica a chance to both exhibit their booth and give a presentation. One of the highlights...
By Jamie Reno, June 15, 2022 BioFluidica presented its LiquidScan, a microfluidic chip that searches a blood sample for rare biomarkers such as CTCs (circulating tumor cells), cell-free DNA (cfDNA), and/or exosomes, which are particles that release naturally from a cell. Rolf Muller, the company’s chief executive officer, noted that the technologies developed by BioFluidica can...
San Diego Union Tribune | By Bradley J. Fikes, August 31, 2018 Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up chemicals, cell fragments and whole cells. But signs of disease may be exceedingly rare, and reliably picking them out has spawned an industry devoted to the task....